🇬🇾

Pharmaceutical Products from Guyana Tariff: 10% (2026)

Tariff Rate Breakdown

10%

Section 122 Base

10%

Effective Rate

Pharmaceutical Products from Guyana represent an important segment of bilateral trade, with approximately $3B in total bilateral trade.

The current tariff framework for pharmaceutical products from Guyana reflects the post-SCOTUS landscape: a 10% base tariff under the Section 301 forced-labor tariff that replaced the flat 10% Section 122 rate on July 24, 2026, which had itself replaced the previously higher IEEPA rates after the Court's February 2026 ruling.

The flat 10% Section 122 tariff was subject to a 150-day statutory time limit and expired on July 24, 2026. It was replaced the same day by USTR's Section 301 forced-labor tariff — a two-tier 10%/12.5% duty on roughly 60 economies (about 99.4% of US imports by value), broader than the earlier 46-country proposal. Guyana's current 10% base surcharge is that forced-labor rate; in August 2026, 25 states sued at the Court of International Trade to block it, but CBP continues collecting it while the case proceeds.

Pharmaceutical Products (HTS Chapter 30) generally enter duty-free at the MFN level, with the base forced-labor tariff as the primary duty. No additional Section 232 or Section 301 surcharges apply to most products in this category from Guyana.

Key products in HTS Chapter 30 imported from Guyana include Vaccines, Antibiotics, Insulin, Bandages, Diagnostic reagents, and Blood products.

Common Products in Chapter 30

VaccinesAntibioticsInsulinBandagesDiagnostic reagentsBlood productsPharmaceutical dosage formsFirst-aid kits

Calculate Your Import Duty

Use our tariff calculator to estimate the exact duty on your pharmaceutical products imports from Guyana.

Open Tariff Calculator

Frequently Asked Questions

What is the current tariff rate on pharmaceutical products from Guyana?

As of mid-2026, pharmaceutical products from Guyana face a base tariff of 10% under the Section 301 forced-labor tariff, which replaced the flat 10% Section 122 rate on July 24, 2026. The effective rate is about 10% on the most-affected products.

Will the tariff on pharmaceutical products from Guyana change?

The flat 10% Section 122 tariff expired July 24, 2026 and was replaced the same day by the Section 301 forced-labor tariff; Guyana's current 10% base surcharge is that two-tier (10%/12.5%) rate, covering roughly 60 economies. In August 2026, 25 states sued to block the forced-labor tariff, but CBP continues collecting it while the case proceeds.

How did the Supreme Court ruling affect pharmaceutical products imports from Guyana?

The Supreme Court's February 20, 2026 ruling struck down IEEPA reciprocal tariffs as exceeding presidential authority. The president signed a replacement flat 10% tariff under Section 122 the same day, effective February 24; that rate expired July 24, 2026 and was replaced by the Section 301 forced-labor tariff (now 10% for Guyana).